Clinical Trial Update: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating salvage therapy that includes epcoritamab (Epcor) followed by autologous stem cell transplant and epcoritamab consolidation in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Follicular Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

Drugs mentioned

• Epcoritamab (Epcor) (epcoritamab)

Snippet

Sponsor: Australasian Leukaemia and Lymphoma Group | Conditions: DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Status: RECRUITING